Dutasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease

Rudolphus

Established Member
My Regimen
Reaction score
73
"The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease"
http://www.sciencedirect.com/science/article/pii/S0028390815001963

This study provides evidence that Dutasteride may have some neuroprotective properties, and could in fact decrease the risk or severity of Parkinson's disease.

"In summary, our results showed that a 5α-reductase inhibitor, Dutasteride has neuroprotective activity preventing in male mice the MPTP-induced loss of several dopaminergic markers."
 

I.D WALKER

Senior Member
Reaction score
869
Figures and tables









  • Neuropharmacology

    Volume 97, October 2015, Pages 86–94


    <img alt="Cover image" src="http://ars.els-cdn.com/content/image/S00283908.gif" class="toprightlogo" />



    The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's Disease







    Highlights


    •The 5α-reductase inhibitors Dutasteride and Finasteride were studied in MPTP mice.
    •Dutasteride prevented the MPTP-induced striatal loss of dopamine concentrations.
    •Dutasteride prevented striatal MPTP-induced loss of DAT and VMAT2 transporters.
    •Finasteride did not protect striatal dopamine concentrations, DAT or VMAT2 levels.
    •Dutasteride and Finasteride prevented MPTP-induced decreases of plasma testosterone.


    Abstract

    Finasteride and Dutasteride are 5α-reductase inhibitors used in the clinic to treat endocrine conditions and were recently found to modulate brain dopamine (DA) neurotransmission and motor behavior. We investigated if Finasteride and Dutasteride have a neuroprotective effect in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) male mice as a model of Parkinson's disease (PD).
    Experimental groups included saline treated controls and mice treated with saline, Finasteride (5 and 12.5 mg/kg) or Dutasteride (5 and 12.5 mg/kg) for 5 days before and 5 days after MPTP administration (4 MPTP injections, 6.5 mg/kg on day 5 inducing a moderate DA depletion) and then they were euthanized.
    MPTP administration decreased striatal DA contents measured by HPLC while serotonin contents remained unchanged. MPTP mice treated with Dutasteride 5 and 12.5 mg/kg had higher striatal DA and metabolites (DOPAC and HVA) contents with a decrease of metabolites/DA ratios compared to saline-treated MPTP mice. Finasteride had no protective effect on striatal DA contents. Tyrosine hydroxylase (TH) mRNA levels measured by in situ hybridization in the substantia nigra pars compacta were unchanged. Dutasteride at 12.5 mg/kg reduced the effect of MPTP on specific binding to striatal DA transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) measured by autoradiography. MPTP reduced compared to controls plasma testosterone (T) and dihydrotestosterone (DHT) concentrations measured by liquid chromatography–tandem mass spectrometry; Dutasteride and Finasteride increased plasma T levels while DHT levels remained low.
    In summary, our results showed that a 5α-reductase inhibitor, Dutasteride has neuroprotective activity preventing in male mice the MPTP-induced loss of several dopaminergic markers.



    Keywords
  • Finasteride;
  • Dutasteride;
  • MPTP;
  • Neuroprotection;
  • Dopamine;
  • Striatum

Corresponding author. Neuroscience Research Unit, Centre Hospitalier Universitaire de Québec, CHUL, 2705 Laurier Boulevard, Quebec City, Quebec G1V 4G2, Canada. Tel.: +1 418 654 2296; fax:


Here's an abstract while we chew over yet another rodent study



 

Rudolphus

Established Member
My Regimen
Reaction score
73
How could it have neuro protective qualities but cause permanent brain fog? This doesn't make much sense.
But does it cause "permanent brain fog" though? I personally am very skeptical of this claim, and it is certainly not true in my own case.
 
Top